Adipocyte-Derived Hormone Leptin Is a Direct Regulator of Aldosterone Secretion, Which Promotes Endothelial Dysfunction and Cardiac Fibrosis

Circulation

Volumn 132, Issue 22, 2015, Pages 2134-2145

  Huby, Anne Cécile ^a   Antonova, Galina ^a   Groenendyk, Jake ^a   Gomez Sanchez, Celso E ^c   Bollag, Wendy B ^a,b   Filosa, Jessica A ^a   De Chantemèle, Eric J Belin ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

Author keywords

adrenal glands; aldosterone; CYP11B2; endothelium; heart; leptin; obesity

Indexed keywords

ALDOSTERONE; ALDOSTERONE SYNTHASE; ANGIOTENSIN II; CALCIUM; LEPTIN; LEPTIN RECEPTOR; MINERALOCORTICOID RECEPTOR;

ADIPOCYTE; ADRENAL CORTEX CELL; ADRENAL GLAND; ADRENERGIC SYSTEM; ADRENOCORTICAL CARCINOMA CELL LINE; ALDOSTERONE BLOOD LEVEL; ALDOSTERONE RELEASE; ANGIOTENSIN BLOOD LEVEL; ARTICLE; BLOOD VESSEL REACTIVITY; CALCIUM CELL LEVEL; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; GENE EXPRESSION; HEART MUSCLE FIBROSIS; HUMAN; HUMAN CELL; HYPERALDOSTERONISM; IMMUNOHISTOCHEMISTRY; MEASUREMENT; OBESITY; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; WESTERN BLOTTING; ZONA GLOMERULOSA; ADRENAL CORTEX; ANIMAL; C57BL MOUSE; CELL CULTURE; CYTOLOGY; FEMALE; FIBROSIS; HEART DISEASE; KNOCKOUT MOUSE; METABOLISM; MOUSE; MOUSE MUTANT; PATHOLOGY; PHYSIOLOGY; RAT; SECRETION (PROCESS); TUMOR CELL LINE; VASCULAR ENDOTHELIUM; WISTAR KYOTO RAT; ZUCKER RAT;

ADIPOCYTES; ADRENAL CORTEX; ALDOSTERONE; ANIMALS; CELL LINE, TUMOR; CELLS, CULTURED; ENDOTHELIUM, VASCULAR; FEMALE; FIBROSIS; HEART DISEASES; HUMANS; LEPTIN; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, OBESE; RATS; RATS, INBRED WKY; RATS, ZUCKER;

EID: 84949315678     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.115.018226     Document Type: Article

References (51)

1. Calhoun DA, Sharma K. The role of aldosteronism in causing obesity-related cardiovascular risk. Cardiol Clin. 2010;28:517-527. doi: 10.1016/j.ccl.2010.04.001.
2. Pimenta E, Calhoun DA. Aldosterone and metabolic dysfunction: an unresolved issue. Hypertension. 2009;53:585-586. doi: 10.1161/HYPERTENSIONAHA.108.123406.
3. Sowers JR, Whaley-Connell A, Epstein M. Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension. Ann Intern Med. 2009;150:776-783.
4. Hattangady NG, Olala LO, Bollag WB, Rainey WE. Acute and chronic regulation of aldosterone production. Mol Cell Endocrinol. 2012;350:151-162. doi: 10.1016/j.mce.2011.07.034.
5. Bochud M, Nussberger J, Bovet P, Maillard MR, Elston RC, Paccaud F, Shamlaye C, Burnier M. Plasma aldosterone is independently associated with the metabolic syndrome. Hypertension. 2006;48:239-245. doi: 10.1161/01.HYP.0000231338.41548.fc.
6. Kidambi S, Kotchen JM, Grim CE, Raff H, Mao J, Singh RJ, Kotchen TA. Association of adrenal steroids with hypertension and the metabolic syndrome in blacks. Hypertension. 2007;49:704-711. doi: 10.1161/01. HYP.0000253258.36141.c7.
7. Grim CE, Cowley AW Jr, Hamet P, Gaudet D, Kaldunski ML, Kotchen JM, Krishnaswami S, Pausova Z, Roman R, Tremblay J, Kotchen TA. Hyperaldosteronism and hypertension: ethnic differences. Hypertension. 2005;45:766-772. doi: 10.1161/01.HYP.0000154364.00763.d5.
8. Hiramatsu K, Yamada T, Ichikawa K, Izumiyama T, Nagata H. Changes in endocrine activities relative to obesity in patients with essential hypertension. J Am Geriatr Soc. 1981;29:25-30.
9. Rocchini AP, Katch VL, Grekin R, Moorehead C, Anderson J. Role for aldosterone in blood pressure regulation of obese adolescents. Am J Cardiol. 1986;57:613-618.
10. Ehrhart-Bornstein M, Lamounier-Zepter V, Schraven A, Langenbach J, Willenberg HS, Barthel A, Hauner H, McCann SM, Scherbaum WA, Bornstein SR. Human adipocytes secrete mineralocorticoid-releasing factors. Proc Natl Acad Sci U S A. 2003;100:14211-14216. doi: 10.1073/pnas.2336140100.
11. Ehrhart-Bornstein M, Arakelyan K, Krug AW, Scherbaum WA, Bornstein SR. Fat cells may be the obesity-hypertension link: human adipogenic factors stimulate aldosterone secretion from adrenocortical cells. Endocr Res. 2004;30:865-870.
12. Nagase M, Yoshida S, Shibata S, Nagase T, Gotoda T, Ando K, Fujita T. Enhanced aldosterone signaling in the early nephropathy of rats with metabolic syndrome: possible contribution of fat-derived factors. J Am Soc Nephrol. 2006;17:3438-3446. doi: 10.1681/ASN.2006080944.
13. de Haro Moraes C, Figueiredo VN, de Faria AP, Barbaro NR, Sabbatini AR, Quinaglia T, Ferreira-Melo SE, Martins LC, Demacq C, Júnior HM. High-circulating leptin levels are associated with increased blood pressure in uncontrolled resistant hypertension. J Hum Hypertens. 2013;27:225-230. doi: 10.1038/jhh.2012.29.
14. Belin de Chantemele EJ, Ali MI, Mintz JD, Rainey WE, Tremblay ML, Fulton DJ, Stepp DW. Increasing peripheral insulin sensitivity by protein tyrosine phosphatase 1b deletion improves control of blood pressure in obesity. Hypertension. 2012;60:1273-1279.
15. Belin de Chantemele EJ, Muta K, Mintz J, Tremblay ML, Marrero MB, Fulton DJ, Stepp DW. Protein tyrosine phosphatase 1b, a major regulator of leptin-mediated control of cardiovascular function. Circulation. 2009;120:753-763.
16. Cheng A, Uetani N, Simoncic PD, Chaubey VP, Lee-Loy A, McGlade CJ, Kennedy BP, Tremblay ML. Attenuation of leptin action and regulation of obesity by protein tyrosine phosphatase 1B. Dev Cell. 2002;2:497-503.
17. Belin de Chantemele EJ, Mintz JD, Rainey WE, Stepp DW. Impact of leptin-mediated sympatho-activation on cardiovascular function in obese mice. Hypertension. 2011;58:271-279.
18. Gomez-Sanchez CE, Qi X, Velarde-Miranda C, Plonczynski MW, Parker CR, Rainey W, Satoh F, Maekawa T, Nakamura Y, Sasano H, Gomez-Sanchez EP. Development of monoclonal antibodies against human CYP11B1 and CYP11B2. Mol Cell Endocrinol. 2014;383:111-117. doi: 10.1016/j.mce.2013.11.022.
19. Parmar J, Key RE, Rainey WE. Development of an adrenocorticotropinresponsive human adrenocortical carcinoma cell line. J Clin Endocrinol Metab. 2008;93:4542-4546. doi: 10.1210/jc.2008-0903.
20. Oki K, Kopf PG, Campbell WB, Luis Lam M, Yamazaki T, Gomez-Sanchez CE, Gomez-Sanchez EP. Angiotensin II and III metabolism and effects on steroid production in the HAC15 human adrenocortical cell line. Endocrinology. 2013;154:214-221. doi: 10.1210/en.2012-1557.
21. Otvos L Jr, Kovalszky I, Riolfi M, Ferla R, Olah J, Sztodola A, Nama K, Molino A, Piubello Q, Wade JD, Surmacz E. Efficacy of a leptin receptor antagonist peptide in a mouse model of triple-negative breast cancer. Eur J Cancer. 2011;47:1578-1584. doi: 10.1016/j.ejca.2011.01.018.
22. Iddings JA, Kim KJ, Zhou Y, Higashimori H, Filosa JA. Enhanced parenchymal arteriole tone and astrocyte signaling protect neurovascular coupling mediated parenchymal arteriole vasodilation in the spontaneously hypertensive rat. J Cereb Blood Flow Metab. 2015;35:1127-1136. doi: 10.1038/jcbfm.2015.31.
23. Takeda M, Tatsumi T, Matsunaga S, Hayashi H, Kimata M, Honsho S, Nishikawa S, Mano A, Shiraishi J, Yamada H, Takahashi T, Matoba S, Kobara M, Matsubara H. Spironolactone modulates expressions of cardiac mineralocorticoid receptor and 11beta-hydroxysteroid dehydrogenase 2 and prevents ventricular remodeling in post-infarct rat hearts. Hypertens Res. 2007;30:427-437. doi: 10.1291/hypres.30.427.
24. Gautron L, Elmquist JK. Sixteen years and counting: an update on leptin in energy balance. J Clin Invest. 2011;121:2087-2093. doi: 10.1172/JCI45888.
25. Hall JE, da Silva AA, do Carmo JM, Dubinion J, Hamza S, Munusamy S, Smith G, Stec DE. Obesity-induced hypertension: role of sympathetic nervous system, leptin, and melanocortins. J Biol Chem. 2010;285:17271-17276. doi: 10.1074/jbc.R110.113175.
26. Zabolotny JM, Bence-Hanulec KK, Stricker-Krongrad A, Haj F, Wang Y, Minokoshi Y, Kim YB, Elmquist JK, Tartaglia LA, Kahn BB, Neel BG. PTP1B regulates leptin signal transduction in vivo. Dev Cell. 2002;2:489-495.
27. Klebig ML, Wilkinson JE, Geisler JG, Woychik RP. Ectopic expression of the agouti gene in transgenic mice causes obesity, features of type II diabetes, and yellow fur. Proc Natl Acad Sci U S A. 1995;92:4728-4732.
28. Bochud M, Nussberger J, Bovet P, Maillard MR, Elston RC, Paccaud F, Shamlaye C, Burnier M. Plasma aldosterone is independently associated with the metabolic syndrome. Hypertension. 2006;48:239-245. doi: 10.1161/01.HYP.0000231338.41548.fc.
29. El-Gharbawy AH, Nadig VS, Kotchen JM, Grim CE, Sagar KB, Kaldunski M, Hamet P, Pausova Z, Gaudet D, Gossard F, Kotchen TA. Arterial pressure, left ventricular mass, and aldosterone in essential hypertension. Hypertension. 2001;37:845-850.
30. Kidambi S, Kotchen JM, Grim CE, Raff H, Mao J, Singh RJ, Kotchen TA. Association of adrenal steroids with hypertension and the metabolic syndrome in blacks. Hypertension. 2007;49:704-711. doi: 10.1161/01. HYP.0000253258.36141.c7.
31. Glasow A, Haidan A, Hilbers U, Breidert M, Gillespie J, Scherbaum WA, Chrousos GP, Bornstein SR. Expression of Ob receptor in normal human adrenals: differential regulation of adrenocortical and adrenomedullary function by leptin. J Clin Endocrinol Metab. 1998;83:4459-4466. doi: 10.1210/jcem.83.12.5337.
32. Ozata M, Ozdemir IC, Licinio J. Human leptin deficiency caused by a missense mutation: multiple endocrine defects, decreased sympathetic tone, and immune system dysfunction indicate new targets for leptin action, greater central than peripheral resistance to the effects of leptin, and spontaneous correction of leptin-mediated defects. J Clin Endocrinol Metab. 1999;84:3686-3695. doi: 10.1210/jcem.84.10.5999.
33. Paz-Filho G, Mastronardi C, Delibasi T, Wong ML, Licinio J. Congenital leptin deficiency: diagnosis and effects of leptin replacement therapy. Arq Bras Endocrinol Metabol. 2010;54:690-697.
34. Guo C, Martinez-Vasquez D, Mendez GP, Toniolo MF, Yao TM, Oestreicher EM, Kikuchi T, Lapointe N, Pojoga L, Williams GH, Ricchiuti V, Adler GK. Mineralocorticoid receptor antagonist reduces renal injury in rodent models of types 1 and 2 diabetes mellitus. Endocrinology. 2006;147:5363-5373. doi: 10.1210/en.2006-0944.
35. Müller-Fielitz H, Lau M, Jöhren O, Stellmacher F, Schwaninger M, Raasch W. Blood pressure response to angiotensin II is enhanced in obese Zucker rats and is attributed to an aldosterone-dependent mechanism. Br J Pharmacol. 2012;166:2417-2429. doi: 10.1111/j.1476-5381.2012.01953.x.
36. Clapham JC, Turner NC. Effects of the glucocorticoid II receptor antagonist mifepristone on hypertension in the obese Zucker rat. J Pharmacol Exp Ther. 1997;282:1503-1508.
37. Osmond JM, Mintz JD, Stepp DW. Preventing increased blood pressure in the obese Zucker rat improves severity of stroke. Am J Physiol Heart Circ Physiol. 2010;299:H55-H61. doi: 10.1152/ajpheart.01111.2009.
38. Bickel CA, Verbalis JG, Knepper MA, Ecelbarger CA. Increased renal Na-K-ATPase, NCC, and beta-ENaC abundance in obese Zucker rats. Am J Physiol Renal Physiol. 2001;281:F639-F648.
39. Riazi S, Khan O, Hu X, Ecelbarger CA. Aldosterone infusion with high-NaCl diet increases blood pressure in obese but not lean Zucker rats. Am J Physiol Renal Physiol. 2006;291:F597-F605. doi: 10.1152/ajprenal.00508.2005.
40. Briones AM, Nguyen Dinh Cat A, Callera GE, Yogi A, Burger D, He Y, Corrêa JW, Gagnon AM, Gomez-Sanchez CE, Gomez-Sanchez EP, Sorisky A, Ooi TC, Ruzicka M, Burns KD, Touyz RM. Adipocytes produce aldosterone through calcineurin-dependent signaling pathways: implications in diabetes mellitus-associated obesity and vascular dysfunction. Hypertension. 2012;59:1069-1078. doi: 10.1161/HYPERTENSIONAHA.111.190223.
41. Armani A, Cinti F, Marzolla V, Morgan J, Cranston GA, Antelmi A, Carpinelli G, Canese R, Pagotto U, Quarta C, Malorni W, Matarrese P, Marconi M, Fabbri A, Rosano G, Cinti S, Young MJ, Caprio M. Mineralocorticoid receptor antagonism induces browning of white adipose tissue through impairment of autophagy and prevents adipocyte dysfunction in high-fat-diet-fed mice. FASEB J. 2014;28:3745-3757. doi: 10.1096/fj.13-245415.
42. Guo C, Ricchiuti V, Lian BQ, Yao TM, Coutinho P, Romero JR, Li J, Williams GH, Adler GK. Mineralocorticoid receptor blockade reverses obesity-related changes in expression of adiponectin, peroxisome proliferator-activated receptor-gamma, and proinflammatory adipokines. Circulation. 2008;117:2253-2261. doi: 10.1161/CIRCULATIONAHA.107.748640.
43. Barrett PQ, Bollag WB, Isales CM, McCarthy RT, Rasmussen H. Role of calcium in angiotensin II-mediated aldosterone secretion. Endocr Rev. 1989;10:496-518. doi: 10.1210/edrv-10-4-496.
44. Spät A, Hunyady L. Control of aldosterone secretion: a model for convergence in cellular signaling pathways. Physiol Rev. 2004;84:489-539. doi: 10.1152/physrev.00030.2003.
45. Takekoshi K, Ishii K, Kawakami Y, Isobe K, Nanmoku T, Nakai T. Ca(2+) mobilization, tyrosine hydroxylase activity, and signaling mechanisms in cultured porcine adrenal medullary chromaffin cells: effects of leptin. Endocrinology. 2001;142:290-298. doi: 10.1210/endo.142.1.7914.
46. Shibuya I, Utsunomiya K, Toyohira Y, Ueno S, Tsutsui M, Cheah TB, Ueta Y, Izumi F, Yanagihara N. Regulation of catecholamine synthesis by leptin. Ann N Y Acad Sci. 2002;971:522-527.
47. Mark ALa, Correia MLGb, Rahmouni Ka, Haynes WGa. Selective leptin resistance: A new concept in leptin physiology with cardiovascular implications. J Hypertens. 2002;20:1245-1250.
48. Whaley-Connell A, Johnson MS, Sowers JR. Aldosterone: role in the cardiometabolic syndrome and resistant hypertension. Prog Cardiovasc Dis. 2010;52:401-409. doi: 10.1016/j.pcad.2009.12.004.
49. Knudson JD, Payne GA, Borbouse L, Tune JD. Leptin and mechanisms of endothelial dysfunction and cardiovascular disease. Curr Hypertens Rep. 2008;10:434-439.
50. Abel ED, Litwin SE, Sweeney G. Cardiac remodeling in obesity. Physiol Rev. 2008;88:389-419. doi: 10.1152/physrev.00017.2007.
51. Zibadi S, Cordova F, Slack EH, Watson RR, Larson DF. Leptin's regulation of obesity-induced cardiac extracellular matrix remodeling. Cardiovasc Toxicol. 2011;11:325-333. doi: 10.1007/s12012-011-9124-0.